Fausch, I.
| The law for mini-organ prototypes in a dish. Mapping the legal status options for organoids in Swiss law, Journal of Law and the Biosciences, Volume 11, Issue 2, July-December 2024, lsae025, https://doi.org/10.1093/jlb/lsae025 |
| Fausch, I., Zeyer-Iyengar, D., Cajiga Morales , R. M., Elger, B., Enzmann, V., & Früh, A. (2025) | Exploring Alternatives to Animal Testing: Scientific, Legal and Ethical Challenges in Developing Novel Alternative Methods with a Focus on Organoids as Potential NAMs. LEOH - Journal of Animal Law, Ethics and One Health, 81-99. https://doi.org/10.58590/leoh.2025.008 |
| Olsena, S., Amos, M., Fausch, I. | Decision-Making Rights of Patients with Limited Capabilities in Healthcare and Mental Healthcare in Estonia, Latvia And Lithuania. Eur J Health Law. 2025 Jul 21;32(4):377-403. doi: 10.1163/15718093-bja10152. PMID: 40696519. |
| Fausch, I., Lau, P.L, Koscik, M., Nordberg, A. (Mai, 2024) | Comments on the WHO Principles for Human Genome Use on behalf of the European Association of Health Law IG on Suprantional Biolaw |
Fausch, I. and Mahalatchimy, A. (Februar, 2025) | “Advanced Therapy Medicinal Products”, Oxford University Press Online Encyclopedia for European Health Law |
| Fausch, I. (1.07.2024) | “Legal Liability for Allocation of Scarce Resources in Health Care in the COVID-19 Pandemic in Switzerland”, Wolters Kluwers International |
| Fausch, I. and Zeyer, D. (2024) | “Angriffe auf KI-Systeme“, Bericht Law Tech Workshop, sic! (3). Available at: https://www.sic-online.ch/fileadmin/user_upload/Sic-Online/2024/documents/174.pdf |
| Fausch, I. et al. (2022) | “Health as a fundamental value. Towards an inclusive and equitable pharmaceutical strategy for the EU”, Veröffentlichung einer gemeinsamen Stellungnahme zur Beratung der Europäischen Kommission bezüglich der EU-Pharmastrategie 2022. Available at:https://shs.hal.science/halshs-03780394 |
| Fausch, I. (2021) | “Development of Personalised Medicine within Hospitals: Myth or Reality?”, Zeitschrift für Stoffrecht 18 (2), pp. 48 - 55. |
| Fausch, I. (2020) | “Personalised Medicine as a challenge for Patent Law”, Carl Heymanns Verlag (Wolters Kluwer), Köln |
| Chmurec, I. (2018) | “iPS cell and iPS cell-based therapies – Swiss and the UK perspective on definition and Regulation” in: Müller / Rosenau (Hrgs.), Stammzellen - iPS-Zellen - Genomeditierung. Stem Cells - iPS Cells - Genome Editing, Nomos Vol. 34, S. 53-64. |
| Chmurec, I. (2017) | “From Lab to Life –Regulations for New Developments in Stem Cell Research”, Zeitschrift für Stoffrecht, 14 (6), pp. 284-290 |
| Chmurec, I., Borer, M. (2017) | “EU Clinical Trial Regulation – New Legal Framework for Multicenter Clinical Trials”, Zeitschrift für Stoffrecht, 14 (2), pp. 111-115 |
| Chmurec, I., Gumbis, J., Pumputienė, R., Narbutas, Š., Balėnė, I. (2015) | “Medical Law in Lithuania”, (1. Ausgabe), Kluwer Law International |
| Chmurec, I. (2014) | “Ethical and religious aspects of organ, tissue and cell transplantation (lit. Etiniai ir religiniai organų, audinių ir ląstelių transplantacijos aspektai)“, Students’ Scientific Society Journal, Vilnius University |